<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01391065</url>
  </required_header>
  <id_info>
    <org_study_id>TMH-IRB 843</org_study_id>
    <nct_id>NCT01391065</nct_id>
  </id_info>
  <brief_title>MR- PET Guided Biologically Optimised Interstitial Brachytherapy</brief_title>
  <acronym>MR-PET Brachy</acronym>
  <official_title>MR-PET Guided Biologically Optimised Interstitial Brachytherapy for Postoperative Recurrent Cervical Cancers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tata Memorial Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tata Memorial Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The proposed two stage study will evaluate patterns of local recurrence after EBRT and
      brachytherapy in spatial reference to baseline functional MRI and FLT/F-Miso PET scan in
      patients undergoing chemoradiotherapy for postoperative recurrences of cervical cancer. The
      first stage of the study will focus on developing MR guided interstitial brachytherapy and
      validating the concept of high risk gross tumor volume (on the basis of functional imaging
      features).

      The second stage thereafter will focus on developing biologically modulated interstitial
      brachytherapy.

      In the proposed two staged study the investigators intend to prospectively evaluate and
      validate concept of HRGTV and develop technique of biologically dose modulated brachytherapy.
      The demonstration of technical feasibility and clinical safety of biologically modulated
      image guided radiotherapy in this pilot study for may pave the way for improving local
      control in patients with postoperative recurrences.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Aims

      Stage I

      Aim 1: To spatially characterize biologically heterogenous subvolumes within the gross tumor
      through multimodality (18 F-Miso/FLT/Functional MR) image fusion.

      Aim 2: To evaluate post external beam radiotherapy (EBRT) response in spatial reference to
      biological heterogeneous sub-volumes on imaging.

      Stage II:

      Aim 3: To evaluate technical feasibility of delivering dose modulated biologically optimized
      interstitial brachytherapy.

      Aim 4: To evaluate acute and late toxicity and quality of life associated with biologically
      optimized brachytherapy
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 23, 2011</start_date>
  <completion_date type="Actual">October 4, 2019</completion_date>
  <primary_completion_date type="Actual">February 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Local Response in spatial reference to High Risk GTV (as identified by functional imaging)</measure>
    <time_frame>3 months after treatment completion</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of Grade III rectal and bladder toxicity with biologically dose modulated brachytherapy</measure>
    <time_frame>2 years after treatment conclusion</time_frame>
    <description>Stage II involves dose modulated brachytherapy wherein higher dose will be delivered to biologically high risk target volume. Saftey will be assessed initially by an interim analysis undertaken at 50 % accrual(median follow up 1 yr). If incidence of grade III-IV rectal and bladder toxicity &gt;15% than the trial will be stopped else continued till target accrual. The technique will be considered to be safe if Grade III bladder and bowel toxicity remain to be under 15%.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Cervical Cancer</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>The study arm will undergo baseline multifunctional PET and MRI scans, before brachytherapy and at follow up</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>MR PET Guided Brachytherapy</intervention_name>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt; 18 years.

          -  ECOG 0 or 1.

          -  Residual/ Recurrent tumor after hysterectomy of cervical cancer.

          -  No visceral metastasis.

          -  No known contraindication to contrast enhanced MRI/PET scan.

          -  Fit for radical treatment (radiotherapy+/-chemotherapy).

        Exclusion Criteria:

          -  Expected survival less than 3 years due to coexisting morbid medical conditions
             precluding radical chemoradiotherapy.

          -  Inguinal or extra-pelvic nodal metastasis (Patients with common iliac nodal
             enlargement in the absence of paraaortic nodal metastasis on PET-CT may be included in
             the study).
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Advanced Centre of Treatment Research and Education In Cancer,Tata Memorial Centre</name>
      <address>
        <city>Navi Mumbai</city>
        <state>Maharashtra</state>
        <zip>410210</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>July 1, 2011</study_first_submitted>
  <study_first_submitted_qc>July 7, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 11, 2011</study_first_posted>
  <last_update_submitted>April 3, 2020</last_update_submitted>
  <last_update_submitted_qc>April 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Tata Memorial Hospital</investigator_affiliation>
    <investigator_full_name>Supriya Sastri (chopra)</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Diffusion Weighted MRI</keyword>
  <keyword>FLT PET</keyword>
  <keyword>F-Miso PET</keyword>
  <keyword>Image Guided Brachytherapy</keyword>
  <keyword>Cervix</keyword>
  <keyword>Postoperative Residual Disease/Postoperative recurrences</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
  </condition_browse>
  <study_docs>
    <study_doc>
      <doc_type>Published article</doc_type>
      <doc_url>https://doi.org/10.1016/j.ijrobp.2019.10.037</doc_url>
    </study_doc>
  </study_docs>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

